Search research articles
Contact Us
Filters
Showing results (31-40 of 80) with videos related to
Page
of 8
Sort By:
Current Colorectal Cancer Reports
|
September 14, 2013
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
Thierry André, Timothy Iveson, Roberto Labianca, et al.
Cancers
|
January 25, 2025
A Comprehensive Approach to Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Annalice Gandini, Stefania Sciallero, Valentino Martelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer
Jim Cassidy, Josep Tabernero, Chris Twelves, et al.
Clinical Drug Investigation
|
September 12, 2008
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting
Francesco Di Costanzo, Roberto Ravasio, Alberto Sobrero, et al.
The Oncologist
|
September 11, 2012
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus
René Adam, Aimery De Gramont, Joan Figueras, et al.
Oncology Research
|
August 24, 2006
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules
Alessio Tempestini, Barbara Caciagli, Maria Morganti, et al.
Arthritis Care & Research
|
November 28, 2025
Experiential Learning for Developing Telehealth and Shared Decision-Making Skills during Rheumatology Fellowship
Alberto Sobrero, Grace A McMahon, Amanda S Alexander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2012
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)
Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 19, 2008
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)
Ivan Popov, Alfredo Carrato, Alberto Sobrero, et al.
Cancer Treatment Reviews
|
September 30, 2015
Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus
René Adam, Aimery de Gramont, Joan Figueras, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 80) with videos related to
Sort By:
Page
of 8
Current Colorectal Cancer Reports
|
September 14, 2013
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
Thierry André, Timothy Iveson, Roberto Labianca, et al.
Cancers
|
January 25, 2025
A Comprehensive Approach to Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Annalice Gandini, Stefania Sciallero, Valentino Martelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer
Jim Cassidy, Josep Tabernero, Chris Twelves, et al.
Clinical Drug Investigation
|
September 12, 2008
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting
Francesco Di Costanzo, Roberto Ravasio, Alberto Sobrero, et al.
The Oncologist
|
September 11, 2012
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus
René Adam, Aimery De Gramont, Joan Figueras, et al.
Oncology Research
|
August 24, 2006
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules
Alessio Tempestini, Barbara Caciagli, Maria Morganti, et al.
Arthritis Care & Research
|
November 28, 2025
Experiential Learning for Developing Telehealth and Shared Decision-Making Skills during Rheumatology Fellowship
Alberto Sobrero, Grace A McMahon, Amanda S Alexander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2012
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)
Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 19, 2008
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)
Ivan Popov, Alfredo Carrato, Alberto Sobrero, et al.
Cancer Treatment Reviews
|
September 30, 2015
Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus
René Adam, Aimery de Gramont, Joan Figueras, et al.
Page
of 8